Modality
ASO
MOA
IL-17i
Target
TIM-3
Pathway
PI3K/AKT
Melanoma
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
Jul 2018
→ Apr 2028
Phase 1Current
NCT04922445
195 pts·Melanoma
2018-07→2028-04·Not yet recruiting
195 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-04-212.1y awayInterim· Melanoma
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P1
Not yet…
Catalysts
Interim
2028-04-21 · 2.1y away
Melanoma
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04922445 | Phase 1 | Melanoma | Not yet recr... | 195 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Nidaratamab | Krystal Biotech | Preclinical | RET | |
| Liratinib | Krystal Biotech | NDA/BLA | TIM-3 | |
| Doxazasiran | Axsome | Phase 1 | TIM-3 |